Physician profile
Mark A Simaga
NPI 1598818270
$11,848.37
in general payments reported to CMS, 2019-2025
60 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $1,435 · 2021: $2,589 · 2022: $2,121 · 2023: $1,853 · 2024: $1,723 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.64 |
| Education | $238.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,338.76 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $828.17 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $807.82 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $541.14 | 2021-2022 | |
| Lilly USA, LLC | $507.39 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Genzyme Corporation | $435.07 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $414.81 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $392.91 | 2021 | |
| Pfizer INC. | $386.32 | 2023-2025 | |
| Ucb, INC. | $375.09 | 2019-2024 | Briviact |
| Biohaven Pharmaceutical Holding Company Ltd. | $373.86 | 2022 | |
| Genentech USA, INC. | $354.89 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Sk Life Science, INC. | $300.94 | 2020-2025 | Xcopri |
| Amgen INC. | $278.51 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $274.64 | 2019-2025 | Daybue, Nuplazid |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $225.17 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $222.61 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lundbeck LLC | $217.82 | 2019-2024 | Vyepti |
| Alexion Pharmaceuticals, INC. | $187.17 | 2021-2024 | Soliris, Ultomiris |
| Acorda Therapeutics, INC | $184.26 | 2019-2024 | Inbrija, Ampyra |
| Boston Scientific Corporation | $175.07 | 2020-2024 | Watchman Flx |
| Biogen, INC. | $174.20 | 2020-2023 | Vumerity, Plegridy, Avonex |
| Csl Behring | $171.57 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $157.33 | 2022-2025 | Hyqvia |
| Silk Road Medical, INC. | $150.00 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Otsuka America Pharmaceutical, INC. | $145.97 | 2023-2025 | Rexulti, Nuedexta |
| Catalyst Pharmaceuticals, INC. | $142.15 | 2020-2025 | Fycompa |
| Avanir Pharmaceuticals, INC. | $132.07 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $129.89 | 2019-2021 | |
| Eisai INC. | $123.37 | 2021-2024 | |
| Upsher-Smith Laboratories LLC | $117.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $113.06 | 2021-2025 | Wainua |
| Neurelis, INC. | $112.42 | 2020-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $109.08 | 2020-2025 | Ingrezza, Ongentys |
| Ekos Corporation | $93.33 | 2019 | |
| Grifols USA, LLC | $93.17 | 2022-2025 | Gamunex-C |
| Abbott Laboratories | $92.46 | 2019-2023 | Infinity |
| Corium, LLC | $85.16 | 2022-2023 | Adlarity |
| Mallinckrodt Hospital Products INC. | $83.96 | 2024-2025 | Acthar |
| Adamas Pharmaceuticals, INC. | $76.36 | 2020-2021 | |
| Chiesi USA, INC. | $73.36 | 2019-2023 | Cleviprex |
| Almatica Pharma LLC | $64.54 | 2021 | |
| Banner Life Sciences, LLC | $59.38 | 2022-2024 | |
| Kyowa Kirin, INC. | $55.47 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $54.22 | 2024 | Aptiom |
| Livanova USA, INC. | $54.15 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $52.28 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $42.95 | 2022-2023 | Onpattro |
| Ceribell, INC. | $42.87 | 2021-2024 | Pocket Eeg Device |
| Assertio Therapeutics, INC. | $34.72 | 2019-2020 | |
| Octapharma USA, INC. | $30.55 | 2021 | |
| Impel Pharmaceuticals INC. | $23.30 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $22.63 | 2025 | Inbrija |
| Idorsia Pharmaceuticals US INC | $21.59 | 2023 | Quviviq |
| Amylyx Pharmaceuticals, INC. | $20.11 | 2023 | Relyvrio |
| Aucta Pharmaceuticals, INC. | $17.90 | 2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $14.99 | 2025 | Tascenso Odt, Bafiertam |
| Merck Sharp & Dohme LLC | $13.13 | 2022 | |
| Allergan, INC. | $12.71 | 2020 | |
| Currax Pharmaceuticals LLC | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Simaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.